Evidence map›Paper›PMID 41824786›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

The ITGB2-COPS3-SOX2 Axis and SOX2 Liquid-Liquid Phase Separation: Dual Mechanisms Governing Osteosarcoma Stemness.

Lei Guo, Zhiqing Zhao, Wei Wang, Jianfang Niu, Bing Wang, Yunfei Lin, Wei Guo, Taiqiang Yan

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lei GuoDepartment of Orthopedics, Peking University First Hospital, Peking University, Beijing, China.
Zhiqing ZhaoDepartment of Orthopedics, Peking University First Hospital, Peking University, Beijing, China.
Wei WangDepartment of Orthopedics, Peking University First Hospital, Peking University, Beijing, China.
Jianfang NiuDepartment of Orthopedics, Peking University First Hospital, Peking University, Beijing, China.
Bing WangDepartment of Orthopedics, Peking University First Hospital, Peking University, Beijing, China.
Yunfei LinDepartment of Orthopedics, Peking University First Hospital, Peking University, Beijing, China.
Wei GuoMusculoskeletal Tumor Center, Peking University People's Hospital, Peking University, Beijing, China.
Taiqiang YanDepartment of Orthopedics, Peking University First Hospital, Peking University, Beijing, China.ORCID https://orcid.org/0000-0003-3982-1052

Funding

National High Level Hospital Clinical Research Funding 2024IR43National Natural Science Foundation of China 81972513National Natural Science Foundation of China 82141120National Natural Science Foundation of China 82372739National Natural Science Foundation of China 82573696Natural Science Foundation of Beijing, China 7232186
6 · The paper itself

Abstract

Osteosarcoma is a highly malignant bone tumor prevalent in adolescents, whose therapeutic challenges stem largely from cancer stem cell (CSC)-mediated chemoresistance and pulmonary metastasis. High-frequency amplification of the 17p11.2 chromosomal region in osteosarcoma represents a key molecular event driving malignant progression. This study focuses on the key gene COPS3 in this region, delving into its molecular mechanisms regulating cancer stemness. The findings show that elevated COPS3 expression strongly correlates with stemness features. Mechanistically, COPS3 binds directly to transcription factor SOX2, inhibiting its ubiquitin-mediated degradation, enhancing its stability and transcriptional activity, and establishing a positive feedback loop that reinforces the stemness phenotype. Furthermore, the extracellular matrix receptor ITGB2 emerges as an upstream regulator promoting COPS3 nuclear translocation. Significantly, this study provides the first evidence that SOX2 undergoes liquid-liquid phase separation (LLPS) in osteosarcoma, a critical mechanism for maintaining cancer stemness. Based on these findings, we identified Z-5891, a highly selective COPS3 inhibitor that suppresses tumor growth and reduces cancer stemness in vitro and in vivo. This study delineates a complete stemness regulatory pathway from microenvironmental signals to nuclear LLPS, thereby providing a novel theoretical framework and a candidate drug for targeting CSCs to overcome drug resistance and metastasis in osteosarcoma.

Indexed as

Bone NeoplasmsNeoplastic Stem CellsOsteosarcomaSOXB1 Transcription FactorsAnimalsCell Line, TumorHumansMicePhase SeparationSOX2 protein, humanSOXB1 Transcription Factorscancer stem cellCOPS3liquid‐liquid phase separationosteosarcomasmall‐molecule inhibitor

Identifiers

PMID41824786
PMCPMC13205827

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.